MDL 3163: The Ozempic Vision-Loss Lawsuits Now Have Their Own Court

Marin & MurphySuper Lawyers® 2014–2024(888) 348-2735

Ozempic (GLP-1) Lawsuit — Free Case Review

The Ozempic Litigation, Honestly Told

Two federal MDLs, no settlements yet, and real court tests ahead — find out in minutes whether your injury and records fit the current criteria.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.

Did this happen to you — or someone you love?

Start your free case reviewTell us anyway

Answered 24/7 · Free & confidential · No fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney's fee is a percentage of the gross recovery, calculated before expenses are deducted.

(888) 348-2735

Partners

Matthew T. Marin & Stefanie A. Murphy

Super Lawyers® honorees · American Association for Justice members

Ozempic inquiries get a personal review — and an honest answer either way, free and without obligation.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state. Do not stop, start, or change any prescribed medication because of anything on this page. Those decisions belong with your prescriber. Attorney Advertising.

On December 15, 2025, the Judicial Panel on Multidistrict Litigation consolidated the GLP-1 NAION vision-loss lawsuits into MDL 3163 in the Eastern District of Pennsylvania before Judge Karen S. Marston — notably, at defendant Eli Lilly’s own request and over plaintiffs’ opposition — and the proceeding has grown from roughly 20 cases to 216 in eight months.

Why a second MDL matters

Courts do not consolidate litigation they expect to stay small. A separate MDL gives the NAION cases their own schedule, their own science, and their own outcome — they will not rise or fall with the stomach-injury cases, and the JPML has already shown it polices that boundary (it declined to sweep blood-clot claims into MDL 3094 in December 2024). The unusual wrinkle here is who asked: Eli Lilly moved for centralization while plaintiffs opposed it, a posture that usually signals defendants expect enough volume to want it managed in one courtroom.

The science that got it here

The arc is short and well-documented: a July 2024 JAMA Ophthalmology study reported elevated NAION risk among semaglutide patients; registry studies in Denmark and Norway followed; in June 2025 the European Medicines Agency concluded NAION is a “very rare” side effect of semaglutide and ordered an EU label update, with Australia’s regulator following in July 2026. The U.S. label, as of this writing, has not been changed — a divergence we document line-by-line in our U.S. vs. EU warning ledger, because it cuts both ways: plaintiffs cite the foreign warnings; the defense will argue FDA looked at the same data and declined to act.

Where the NAION track stands

Early, and honestly so: no dismissals, no Daubert rulings, no trial or bellwether date — and no verdicts or settlements. In July 2026 the court entered a case-management order allowing early motion practice on general causation and preemption, adopting the disciplined template that produced the stomach-injury track’s testing requirements. On August 27, 2026 it went further: MDL 3163’s Case Management Order No. 14 set a full pretrial schedule through August 2027 — proposed plaintiff fact sheets due September 25, 2026, the master complaint due October 28, 2026, fact discovery closing December 18, 2026 for Lilly and February 26, 2027 for Novo, and Rule 702 and summary judgment motions due July 2, 2027 — and Case Management Order No. 15 established a time and expense protocol and common benefit fund. The schedule is pretrial only; it sets no trial date. New Jersey has also created parallel state-court multicounty litigation for these cases in Bergen County. If NAION happened to you or someone you love, the practical starting points are our NAION overview and, for the spouses and adult children who so often do this research, the caregiver guide.

Common questions